• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过虚拟筛选发现天然产物作为新型强效法尼醇X受体拮抗剂

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening.

作者信息

Diao Yanyan, Jiang Jing, Zhang Shoude, Li Shiliang, Shan Lei, Huang Jin, Zhang Weidong, Li Honglin

机构信息

Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai, China.

Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai, China.

出版信息

Front Chem. 2018 Apr 30;6:140. doi: 10.3389/fchem.2018.00140. eCollection 2018.

DOI:10.3389/fchem.2018.00140
PMID:29761098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5936786/
Abstract

Farnesoid X receptor (FXR) is a member of nuclear receptor family involved in multiple physiological processes through regulating specific target genes. The critical role of FXR as a transcriptional regulator makes it a promising target for diverse diseases, especially those related to metabolic disorders such as diabetes and cholestasis. However, the underlying activation mechanism of FXR is still a blur owing to the absence of proper FXR modulators. To identify potential FXR modulators, an in-house natural product database (NPD) containing over 4,000 compounds was screened by structure-based virtual screening strategy and subsequent hit-based similarity searching method. After the yeast two-hybrid (Y2H) assay, six natural products were identified as FXR antagonists which blocked the CDCA-induced SRC-1 association. The IC values of compounds , a diterpene bearing polycyclic skeleton, and , named daphneone with chain scaffold, are as low as 1.29 and 1.79 μM, respectively. Compared to the control compound guggulsterone (IC = 6.47 μM), compounds and displayed 5- and 3-fold higher antagonistic activities against FXR, respectively. Remarkably, the two representative compounds shared low topological similarities with other reported FXR antagonists. According to the putative binding poses, the molecular basis of these antagonists against FXR was also elucidated in this report.

摘要

法尼酯X受体(FXR)是核受体家族的成员,通过调节特定靶基因参与多种生理过程。FXR作为转录调节因子的关键作用使其成为多种疾病,尤其是与糖尿病和胆汁淤积等代谢紊乱相关疾病的有前景的治疗靶点。然而,由于缺乏合适的FXR调节剂,FXR的潜在激活机制仍不清楚。为了鉴定潜在的FXR调节剂,通过基于结构的虚拟筛选策略和随后基于命中的相似性搜索方法,对一个包含4000多种化合物的内部天然产物数据库(NPD)进行了筛选。经过酵母双杂交(Y2H)分析,六种天然产物被鉴定为FXR拮抗剂,它们阻断了CDCA诱导的SRC-1结合。化合物1(一种具有多环骨架的二萜)和化合物2(名为具有链状支架的瑞香酮)的IC值分别低至1.29和1.79μM。与对照化合物孕烯醇酮(IC = 6.47μM)相比,化合物1和化合物2对FXR的拮抗活性分别高5倍和3倍。值得注意的是,这两种代表性化合物与其他报道的FXR拮抗剂的拓扑相似性较低。根据推测的结合模式,本报告还阐明了这些拮抗剂针对FXR的分子基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/2166b2ebce1a/fchem-06-00140-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/0f9be03c00f9/fchem-06-00140-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/6d023b1a0391/fchem-06-00140-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/377bcf13f7c9/fchem-06-00140-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/a7111b59e06f/fchem-06-00140-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/2166b2ebce1a/fchem-06-00140-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/0f9be03c00f9/fchem-06-00140-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/6d023b1a0391/fchem-06-00140-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/377bcf13f7c9/fchem-06-00140-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/a7111b59e06f/fchem-06-00140-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4391/5936786/2166b2ebce1a/fchem-06-00140-g0005.jpg

相似文献

1
Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening.通过虚拟筛选发现天然产物作为新型强效法尼醇X受体拮抗剂
Front Chem. 2018 Apr 30;6:140. doi: 10.3389/fchem.2018.00140. eCollection 2018.
2
Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.通过三维形状相似性搜索和基于结构的虚拟筛选发现新型非甾体类法尼醇X受体调节剂。
Chem Biol Drug Des. 2015 Apr;85(4):481-7. doi: 10.1111/cbdd.12432. Epub 2014 Oct 10.
3
Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.发现并优化 1,3,4-三取代吡唑啉酮衍生物作为新型强效非甾体法尼醇 X 受体 (FXR) 选择性拮抗剂。
J Med Chem. 2012 Aug 23;55(16):7037-53. doi: 10.1021/jm3002718. Epub 2012 Aug 10.
4
Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists.新型 SIPI-7623 衍生物的合成及生物评价作为法尼醇 X 受体 (FXR) 拮抗剂。
Mol Divers. 2019 Feb;23(1):19-33. doi: 10.1007/s11030-018-9843-2. Epub 2018 Jul 4.
5
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.新型强效选择性法尼醇X受体拮抗剂化学类型发现中恶二唑核心的研究
ACS Med Chem Lett. 2019 Jan 10;10(4):504-510. doi: 10.1021/acsmedchemlett.8b00534. eCollection 2019 Apr 11.
6
Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies.Licraside作为新型强效FXR激动剂用于缓解胆汁淤积:基于结构的药物发现与生物学评价研究
Front Pharmacol. 2023 Jun 15;14:1197856. doi: 10.3389/fphar.2023.1197856. eCollection 2023.
7
Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.杨芽宁通过体内和体外激活法尼醇 X 受体来防止胆汁淤积和肝毒性。
Toxicol Appl Pharmacol. 2018 Jun 1;348:105-116. doi: 10.1016/j.taap.2018.04.015. Epub 2018 Apr 14.
8
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.三取代吡唑甲酰胺类似物作为法尼醇X受体新型强效拮抗剂的鉴定
Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. doi: 10.1016/j.bmc.2014.04.014. Epub 2014 Apr 16.
9
Discovery of natural estrogen receptor modulators with structure-based virtual screening.基于结构的虚拟筛选发现天然雌激素受体调节剂。
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3329-33. doi: 10.1016/j.bmcl.2013.03.105. Epub 2013 Apr 3.
10
The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone.核激素受体法尼醇X受体(FXR)可被雄甾酮激活。
Endocrinology. 2006 Sep;147(9):4025-33. doi: 10.1210/en.2005-1485. Epub 2006 May 4.

引用本文的文献

1
Integrating deep learning and molecular dynamics simulations for FXR antagonist discovery.整合深度学习与分子动力学模拟以发现法尼醇X受体拮抗剂
Mol Divers. 2025 Apr 2. doi: 10.1007/s11030-025-11145-2.
2
Biocatalytic diversification of abietic acid in Streptomyces.链霉菌中枞酸的生物催化多样化
J Ind Microbiol Biotechnol. 2024 Dec 31;52. doi: 10.1093/jimb/kuaf003.
3
Farnesoid X receptor regulators from natural products and their biological function.天然产物来源的法尼醇 X 受体调节剂及其生物学功能。

本文引用的文献

1
Protein-Protein Interactions: Yeast Two-Hybrid System.蛋白质-蛋白质相互作用:酵母双杂交系统
Methods Mol Biol. 2017;1615:177-187. doi: 10.1007/978-1-4939-7033-9_14.
2
Farnesoid X Receptor an Emerging Target to Combat Obesity.法尼酯X受体:对抗肥胖的新兴靶点
Dig Dis. 2017;35(3):185-190. doi: 10.1159/000450909. Epub 2017 Mar 1.
3
The ChEMBL database in 2017.2017年的ChEMBL数据库。
J Tradit Chin Med. 2023 Jun;43(3):618-626. doi: 10.19852/j.cnki.jtcm.20230404.002.
4
Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis.胆汁酸-FXR-FGF15/19 信号轴的分子基础。
Int J Mol Sci. 2022 May 27;23(11):6046. doi: 10.3390/ijms23116046.
5
Farnesoid X receptor (FXR): Structures and ligands.法尼酯X受体(FXR):结构与配体
Comput Struct Biotechnol J. 2021 Apr 20;19:2148-2159. doi: 10.1016/j.csbj.2021.04.029. eCollection 2021.
6
Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor.多酚诱导的葡萄糖代谢改善与胆汁酸信号传导至肠道法尼醇 X 受体有关。
BMJ Open Diabetes Res Care. 2020 Aug;8(1). doi: 10.1136/bmjdrc-2020-001386.
7
The Gastrointestinal Tract as Prime Site for Cardiometabolic Protection by Dietary Polyphenols.膳食多酚对胃肠道的心脏代谢保护作用。
Adv Nutr. 2019 Nov 1;10(6):999-1011. doi: 10.1093/advances/nmz038.
8
Nuclear Receptor Metabolism of Bile Acids and Xenobiotics: A Coordinated Detoxification System with Impact on Health and Diseases.核受体对胆汁酸和外源性化学物质的代谢:一种协调解毒系统,对健康和疾病有影响。
Int J Mol Sci. 2018 Nov 17;19(11):3630. doi: 10.3390/ijms19113630.
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. doi: 10.1093/nar/gkw1074. Epub 2016 Nov 28.
4
Guggulsterone and Its Role in Chronic Diseases.古古甾酮及其在慢性病中的作用。
Adv Exp Med Biol. 2016;929:329-361. doi: 10.1007/978-3-319-41342-6_15.
5
An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.肠道微生物群-法尼酯X受体轴调节代谢性疾病。
Gastroenterology. 2016 Nov;151(5):845-859. doi: 10.1053/j.gastro.2016.08.057. Epub 2016 Sep 14.
6
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.奥贝胆酸治疗原发性胆汁性胆管炎的安慰剂对照临床试验。
N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.
7
Role of farnesoid X receptor in cholestasis.法尼酯X受体在胆汁淤积中的作用。
J Dig Dis. 2016 Aug;17(8):501-509. doi: 10.1111/1751-2980.12378.
8
Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor.小分子NDB(N-苄基-N-(3-叔丁基-4-羟基苯基)-2,6-二氯-4-(二甲氨基)苯甲酰胺)作为法尼醇X受体α(FXRα)的选择性拮抗剂在稳定受体同二聚化中的结构基础。
J Biol Chem. 2015 Aug 7;290(32):19888-99. doi: 10.1074/jbc.M114.630475. Epub 2015 Jun 22.
9
Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.超越胆汁酸:用天然和合成配体靶向法尼醇X受体(FXR)
Curr Top Med Chem. 2014;14(19):2129-42. doi: 10.2174/1568026614666141112094058.
10
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.微生物组重塑导致肠道法尼醇 X 受体信号抑制和肥胖减少。
Nat Commun. 2013;4:2384. doi: 10.1038/ncomms3384.